Hutchison China MediTech Limited (HCM) Reaches $4559.79 After 4.00% Up Move; Marinemax (HZO) Sellers Decreased By 0.63% Their Shorts

November 14, 2017 - By Adrian Erickson

The stock of Hutchison China MediTech Limited (LON:HCM) is a huge mover today! The stock decreased 0.33% or GBX 15.21 on November 14, reaching GBX 4559.79. About 917 shares traded. Hutchison China MediTech Limited (LON:HCM) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.The move comes after 5 months positive chart setup for the $4.03B company. It was reported on Nov, 14 by Barchart.com. We have $4742.18 PT which if reached, will make LON:HCM worth $161.20 million more.

Marinemax Incorporated (NYSE:HZO) had a decrease of 0.63% in short interest. HZO’s SI was 2.80M shares in November as released by FINRA. Its down 0.63% from 2.82M shares previously. With 415,700 avg volume, 7 days are for Marinemax Incorporated (NYSE:HZO)’s short sellers to cover HZO’s short positions. The SI to Marinemax Incorporated’s float is 12.54%. About 351,511 shares traded. MarineMax Inc (NYSE:HZO) has risen 12.03% since November 14, 2016 and is uptrending. It has underperformed by 4.67% the S&P500.

MarineMax, Inc. is a recreational boat and yacht dealer in the United States. The company has market cap of $544.21 million. Through 56 retail locations in Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Minnesota, Missouri, New Jersey, New York, North Carolina, Ohio, Oklahoma, Rhode Island, and Texas, the Company sold new and used recreational boats, including pleasure and fishing boats, as of September 30, 2016. It has a 21.79 P/E ratio. The Firm also sells related marine products, including engines, trailers, parts and accessories.

Investors sentiment decreased to 1.11 in Q2 2017. Its down 0.24, from 1.35 in 2017Q1. It fall, as 21 investors sold MarineMax Inc shares while 34 reduced holdings. 19 funds opened positions while 42 raised stakes. 23.29 million shares or 2.11% more from 22.81 million shares in 2017Q1 were reported. Rice Hall James Associate Lc invested 0.09% of its portfolio in MarineMax Inc (NYSE:HZO). Great West Life Assurance Co Can owns 0% invested in MarineMax Inc (NYSE:HZO) for 36,134 shares. Goldman Sachs Grp Inc Inc, a New York-based fund reported 82,318 shares. Amer stated it has 0% of its portfolio in MarineMax Inc (NYSE:HZO). Moreover, Thomson Horstmann And Bryant has 0.8% invested in MarineMax Inc (NYSE:HZO). Jpmorgan Chase And accumulated 0% or 41,217 shares. Riverhead Ltd Limited Liability Company accumulated 2,297 shares. Product Ptnrs Limited Co holds 0.08% of its portfolio in MarineMax Inc (NYSE:HZO) for 98,300 shares. Schwab Charles Invest Mgmt holds 112,921 shares. Manatuck Hill Ptnrs accumulated 0.87% or 88,600 shares. 25,000 are held by New York State Common Retirement Fund. Victory Cap Management reported 74,795 shares. Millennium Mngmt invested 0% of its portfolio in MarineMax Inc (NYSE:HZO). Deutsche Bankshares Ag stated it has 61,411 shares. Metropolitan Life Insurance Comm Ny holds 17,546 shares.

Among 8 analysts covering Marinemax (NYSE:HZO), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Marinemax had 16 analyst reports since July 24, 2015 according to SRatingsIntel. Citigroup maintained it with “Buy” rating and $20 target in Monday, October 2 report. The rating was maintained by Stephens on Monday, September 14 with “Overweight”. The stock of MarineMax Inc (NYSE:HZO) earned “Buy” rating by B. Riley & Co on Wednesday, November 1. The stock has “Buy” rating by B. Riley & Co on Thursday, October 26. The firm earned “Neutral” rating on Wednesday, January 25 by Wedbush. The firm has “Buy” rating by Craig Hallum given on Thursday, December 3. The company was upgraded on Tuesday, August 18 by Longbow. The rating was initiated by Citigroup on Friday, February 10 with “Buy”. The stock of MarineMax Inc (NYSE:HZO) has “Buy” rating given on Tuesday, October 31 by SunTrust.

Among 2 analysts covering Hutchison China Meditech Ltd (LON:HCM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Hutchison China Meditech Ltd has GBX 3840 highest and GBX 1750 lowest target. GBX 3840’s average target is -15.79% below currents GBX 4559.79 stock price. Hutchison China Meditech Ltd had 32 analyst reports since July 28, 2015 according to SRatingsIntel. Beaufort Securities maintained Hutchison China MediTech Limited (LON:HCM) on Tuesday, March 22 with “Buy” rating. On Wednesday, August 3 the stock rating was maintained by Beaufort Securities with “Buy”. The firm has “Buy” rating by Panmure Gordon given on Monday, February 20. On Monday, December 5 the stock rating was maintained by Panmure Gordon with “Buy”. The rating was maintained by Beaufort Securities on Wednesday, April 13 with “Buy”. The stock of Hutchison China MediTech Limited (LON:HCM) earned “Buy” rating by Beaufort Securities on Friday, March 18. The firm earned “Buy” rating on Thursday, June 22 by Panmure Gordon. The rating was maintained by Beaufort Securities on Monday, March 6 with “Buy”. The company was maintained on Tuesday, July 28 by Panmure Gordon. Beaufort Securities maintained the stock with “Buy” rating in Friday, June 30 report.

Hutchison China MediTech Limited is a China-based, globally-focused healthcare group. The company has market cap of 4.03 billion GBP. The Firm researches, develops, makes and sells pharmaceuticals and health-related consumer products. It has a 283.36 P/E ratio. The Company’s Innovation Platform focuses on discovering and developing therapeutics in oncology and autoimmune diseases for the global market.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.